Catalyst
Results of the trial and subsequent publications on taVNS efficacy and safety in postoperative settings.
Humanexa recommends Monitor.
Date
July 17, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.